A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice

Anne-Cécile Durieux1, Alban Vignaud, Bernard Prudhon

  • 1Université Pierre et Marie Curie-Paris 6, IFR14, Paris F-75013, France.

Human Molecular Genetics
|September 23, 2010
PubMed

Insights

A new mouse model reveals dynamin 2 (DNM2) mutations cause autosomal dominant centronuclear myopathy (AD-CNM) by disrupting muscle cell trafficking and function. This model aids in understanding disease mechanisms and developing therapies for this rare genetic muscle disorder.

Area of Science:

  • Muscle Biology
  • Genetics
  • Cellular Biology

Background:

  • Autosomal dominant centronuclear myopathy (AD-CNM) is linked to mutations in the dynamin 2 (DNM2) gene.
  • DNM2 plays a critical role in endocytosis and intracellular membrane trafficking.

Purpose of the Study:

  • To investigate the pathomechanisms of AD-CNM by creating a knock-in mouse model with a common DNM2 mutation (KI-Dnm2(R465W)).
  • To analyze the resulting myopathy's characteristics, including muscle involvement, cellular abnormalities, and potential therapeutic targets.

Main Methods:

  • Generated heterozygous (HTZ) and homozygous (HMZ) KI-Dnm2(R465W) mice.
  • Assessed muscle contractile properties, histology, gene expression, and protein localization in muscle fibers.
  • Examined clathrin-mediated endocytosis in embryonic fibroblasts.

Main Results:

  • HTZ mice developed progressive myopathy with muscle atrophy, mitochondrial/reticular network abnormalities, and altered calcium levels.
  • DNM2 localized to trafficking regions, and dysferlin accumulation was observed in HTZ muscle fibers and patient biopsies.
  • HMZ mice exhibited embryonic lethality, likely due to impaired endocytosis.

Conclusions:

  • The KI-Dnm2(R465W) mouse model recapitulates key features of DNM2-related myopathy.
  • Dysferlin accumulation in muscle is a potential new biomarker for DNM2-CNM.
  • This model is crucial for studying DNM2 function, disease mechanisms, and therapeutic strategies for AD-CNM.